로고

engKR
menu

ABOUT US

CEO MESSAGE

CEO and President of RPEXBIO Co., Oh Jong-Won

"RPEX BIO, a company committed to advancing human health and healthcare."

RPEXBIO is committed to contributing to disease prevention and treatment through pioneering RNA-based technologies. We strive to fulfill our social responsibility for a better future by relentlessly pursuing research and innovation.

With a mission to develop innovative RNA-based technologies and create novel pharmaceuticals, we are focused on developing RNA-based biologics for emerging viruses and refractory diseases. Our short-term goal is to develop safe and effective COVID-19 mRNA vaccines using non-modified nucleic acids and to expand our efforts to develop various mRNA vaccines and therapies, contributing to global public health and wellness.

RPEXBIO aims to advance healthcare technology and enhance human health through the creation of various RNA-based biopharmaceuticals with improved efficacy and safety, utilizing our innovative mRNA scaffold platform and RNA virus reverse genetics-based self-replicating RNA platform.

All RPEXBIO employees will strive to enhance our capabilities with relentless challenges and passion to realize our vision and evolve into a leading global RNA technology company. Furthermore, based on the company's mission and vision, we will prioritize corporate social responsibility and the spirit of sharing, striving to contribute to the sustainable development and coexistence of a healthy humanity.

Best regards,

CEO and President of RPEXBIO Co.,  

Oh Jong-Won sign

RPEXBIO

RPEXBIO dreams of a healthy future for humanity.

Education

  • Bachelor's/Master's Degree, Department of Biotechnology, Yonsei University, Republic of Korea
  • Ph.D. in Molecular Virology, University of Massachusetts, Amherst

Positions Held

  • Professor at Yonsei University (2000.03 - present)
  • President of the Korean Society for Microbiology and Biotechnology (2024)
  • Member of the National Strategy Technology Coordination Committee of the National Science and Technology Advisory Council (2024 - 2025)
  • Member of the Special Committee on Infectious Diseases of the National Science and Technology Advisory Council (2021 - 2023)
  • Member of the Core Technology Committee for Infectious Disease Basic Origins of the Ministry of Science and ICT (2022 - present)
  • Member of the KISTEP National Strategic Technology Advanced Biotechnology Subcommittee (2022.07): Awarded for Contributions to
    National Strategic Technology Policy Formulation (January 31, 2023, Commendation from the Minister of Science and ICT, No. 22-03899)
  • Specialist Committee Member for Infectious Disease Research Planning, Division of Emerging Infections, Korea National Institute of Health
    (2022.10 - 2023.02)
  • Editor-in-Chief of the Journal of Microbiology and Biotechnology (2021 - 2023)
  • Member of the Advisory Committee for the National Basic Virus Research Institute, Ministry of Science and ICT (2019),
    Establishment Preparatory Committee (2020)
  • President of the Hepatitis Virus Research Society (2017 - 2018)
  • Director of the Yonsei University Biotechnology Industrialization Research Institute (2009 - 2011)
  • Visiting Researcher at the U.S. FDA Biologics (2006)
  • Researcher at Howard Hughes Medical Institute, Keck School of Medicine of USC (1996 - 2000.02)
  • Researcher at CJ Research Institute (1987-1991)/Visiting Researcher at Eugene Tech Intl. (NJ, USA) (1989)